173,470 Shares in Illumina, Inc. $ILMN Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 173,470 shares of the life sciences company’s stock, valued at approximately $30,501,000.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. OneDigital Investment Advisors LLC acquired a new stake in shares of Illumina during the second quarter worth $252,000. Plato Investment Management Ltd bought a new stake in shares of Illumina during the 2nd quarter valued at about $948,000. Baxter Bros Inc. bought a new stake in shares of Illumina during the 2nd quarter valued at about $295,000. Uniting Wealth Partners LLC acquired a new stake in Illumina during the second quarter worth about $352,000. Finally, Old West Investment Management LLC acquired a new stake in Illumina during the second quarter worth about $22,472,000. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider owned 20,338 shares in the company, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,416,384 shares of company stock valued at $256,164,151. 2.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on ILMN shares. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Guggenheim increased their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Finally, Barclays upped their price objective on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $188.40.

Illumina Stock Performance

ILMN stock opened at $213.24 on Friday. The company has a 50-day simple moving average of $186.84 and a 200 day simple moving average of $151.97. The company has a market capitalization of $32.20 billion, a P/E ratio of 39.78, a PEG ratio of 2.89 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $220.32.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the company earned $1.19 EPS. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.